key: cord-0927227-3lsoi2w8
authors: Wang, Yifei; Upadhyay, Akshaya; Pillai, Sangeeth; Khayambashi, Parisa; Tran, Simon D.
title: Saliva as a diagnostic specimen for SARS‐CoV‐2 detection: A scoping review
date: 2022-04-27
journal: Oral Dis
DOI: 10.1111/odi.14216
sha: 6a7c50be3c077feff8ee014ed05c9812cf8a0978
doc_id: 927227
cord_uid: 3lsoi2w8

OBJECTIVES: This scoping review aims to summarize the diagnostic value of saliva assessed from current studies that (1) compare its performance in reverse transcriptase‐polymerase chain reaction testing to nasopharyngeal swabs, (2) evaluate its performance in rapid and point‐of‐care COVID‐19 diagnostic tests, and (3) explore its use as a specimen for detecting anti‐SARS‐CoV‐2 antibodies. MATERIALS AND METHODS: A systematic search was performed on the following databases: Medline and Embase (Ovid), World Health Organization, Centers for Disease Control and Prevention, and Global Health (Ovid) from January 2019 to September 2021. Of the 657 publications identified from the searches, n = 146 articles were included in the final scoping review. RESULTS: Our findings showcase that salivary samples exceed nasopharyngeal swabs in detecting SARS‐CoV‐2 using reverse transcriptase‐polymerase chain reaction testing in several studies. A select number of rapid antigen and point‐of‐care tests from the literature were also identified capable of high detection rates using saliva. Moreover, anti‐SARS‐CoV‐2 antibodies have been shown to be detectable in saliva through biochemical assays. CONCLUSION: We highlight the potential of saliva as an all‐rounded specimen in detecting SARS‐CoV‐2. However, future large‐scale clinical studies will be needed to support its widespread use as a non‐invasive clinical specimen for COVID‐19 testing.

Saliva and oral fluids have been increasingly used for the detection of various systemic diseases and infections (Javaid et al., 2016) .

With respect to COVID-19, there is currently evidence showing multiple pathways through which SARS-CoV-2 can show presence in saliva: through spread from the upper/lower respiratory tract, from gingival crevicular fluid, or from direct infection of the salivary glands which can then act as a viral reservoir (Han & Ivanovski, 2020) . Moreover, saliva collection is economical, is less invasive and more comfortable for patients, and utilizes minimal equipment . Early studies evaluating SARS-CoV-2 RT-PCR using saliva samples reported detection rates of viral ribonucleic acid (RNA) as high as 90% as well as high sensitivity and specificity values at 0.88 and 0.92, respectively (Atieh et al., 2021) . Further studies have demonstrated that saliva specimens show positive test results even when other respiratory specimens of the same patient test negative for SARS-CoV-2 (Hamid et al., 2020) .

Saliva may also provide information regarding the course of the disease. Viral load has been found to be highest in saliva specimens during the first week of symptom manifestation and serum antibodies against SARS-CoV-2 have been detected in patients while viral RNA was still detectable in saliva (Hamid et al., 2020) . Although the extent of COVID-19 antibodies in saliva is still largely unknown, salivary immunoglobin G (IgG) profiles in general have been shown to be highly similar to plasma IgG profiles for a large number of antigens (Ceron et al., 2020) . Therefore, saliva may have the potential to play a major role in COVID-19 diagnosis and disease progression monitoring, from detecting viral loads not evident in respiratory specimens to screening for immunity. However, large-scale evaluation of saliva-based COVID-19 diagnostic tests compared to the current standard NPS-based tests have yet to be conducted. Furthermore, the role of saliva as a sample for use in rapid antigen and point-ofcare (POC) tests may also require further investigation.

The aim of this review was to provide insight on the current available evidence regarding the efficacy of saliva as a specimen in RT-PCR-based COVID-19 diagnostic tests compared to NPS specimens, as a specimen for rapid antigen/POC COVID-19 diagnostic tests, and its potential for COVID-19 immunity screening.

A scoping review was conducted using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Scoping Reviews checklist (Tricco et al., 2018) . 

The following inclusion criteria were used for screening search results: Articles must be primary research studies, within the publication range 01/01/2019-09/27/2021, in the English language, and contain a study sample of at least 10 confirmed COVID-19positive patients. Included articles were grouped into the following three categories: (1) Saliva as a RT-PCR Specimen for  (2)

Antibody Testing with Saliva. Review articles, case studies, animal studies, and letters to the editor were excluded from the study.

Screening of search results was performed independently by three authors (Y.W., A.U., and P.K.) on Rayyan QCRI. Each author was blinded from the screening results of the other two authors, and all three authors convened after completing independent screening to resolve disagreements through discussion to reach the final decision on included articles. Duplicate articles were excluded. One investigator was assigned to each of the three categories (A.U., Y.W., and P.K.) to extract data from the articles. The final sets of included articles were summarized in Figure 1 and Tables 1-3 along with their relevant details.

Details of the study selection process are described in the PRISMA flow diagram presented by Figure 1 . In summary, a total of 657 publications were found through search results from databases. After title and abstract screening and removing duplicates, 224 articles were retrieved along with full text versions for manual assessment.

Finally, a total of 146 eligible articles were included in the present review.

A plethora of literature has followed utilizing saliva as a diagnostic tool, owing to the evidence of SARS-CoV-2 presence in saliva (Table 1 ). Studies that made the cutoff criteria for number of patients had sample sizes ranging from 13 to 3000. The cohorts included symptomatic as well as asymptomatic patients, patients tested in outpatient departments, general surveys, hospitalized patients, and healthcare workers. Genes amplified for RT-PCR detection were most commonly the E (Envelope) (n = 38), N (Nucleocapsid) (n = 34), ORF1ab (Open Reading Frame) (n = 31), RdRp (RNA-dependent RNA polymerase) (n = 24), N1 and N2 (n = 18), S (Spike) (10), and ORF8 (n = 1). Samples collected varied from saliva, naso-oropharyngeal swabs, anterior nasal swabs, deep throat swabs, gargles, rinses, and cerumen. Different sampling techniques for saliva included drool, spit, gingival fluid, and sputum, and were either self-collected or collected under healthcare worker supervision/assistance. A few cases included a sample-specific collection time, such as morning only samples. The disease states extended from general population and healthcare worker surveys in asymptomatic individuals, to symptomatic and hospitalized patients at the convalescent phase of the disease.

Sensitivity recorded for saliva samples included values from 44% (Sutjipto et al., 2020) , 64% (Kim et al., 2020) , and 95.5% . Specificity for SARS-CoV-2 in saliva ranged from 98.5% (95% CI 96.8-99.5) to 99% (Smith-Jeffcoat et al., 2021) . When compared to standard NPS samples, saliva showed a positive predictive value (PPV) of 90% (95% CI 79%-97%) and a negative predictive value (NPV) 97% (95% CI 96%-98%) (Smith-Jeffcoat et al., 2021) .

Cycle threshold (Ct) values range in saliva around 24-40 (Azzi et al., 2020a (Azzi et al., , 2020b Barra et al., 2021) , with 28.5-35 for the ORF1ab gene and 28.4-33.7 for the N gene as observed by Pasomub and colleagues (Pasomsub et al., 2021) . Early morning samples had the highest viral load in hospitalized patients . Better detection in later stages was also suggested, as dual testing in both positive and recovering patients may limit the spread from such patients by ensuring an appropriate isolation period Sahajpal et al., 2021) . There is a positive correlation between saliva and NPS samples (Aydin et al., 2021; Matic et al., 2021) with positive percent agreement (PPA) ranging from 66.7% (Ku et al., 2021; Senok et al., 2020) to 100% (Cassinari et al., 2021; Mendoza et al., 2021) . More concordance was seen for negative results with negative percent agreement (NPA) values at 91.7% (Ku et al., 2021) , 98% (Paliksa et al., 2021; Senok et al., 2020) , and 100% (Potter et al., 2021) .

As is the case of Ct values/viral load, current evidence regarding the detection rates between saliva and NPS samples is debatable. Moreno-Contreras and colleagues concluded saliva samples to be more reliable than NPS samples, with detection rates of 86.2% versus 65%, respectively (Moreno-Contreras et al., 2020) . Similarly, Iwasaki and colleagues observed a detection rate of 95.5% in saliva samples, 87.5% for sputum, and 53% for NPS . Similar conclusions were made by several authors with variable sample sizes (Ota et al., 2021; Rao et al., 2020; Rao et al., 2021; Teo et al., 2021; Wong et al., 2020; Wyllie et al., 2020; Yokota et al., 2021) . No significant difference between the sensitivity or Ct values of saliva and NPS samples was observed on various instances as well (Sun et al., 2021) . On the contrary, NPS was found to be 17% more sensitive than saliva by Jamal and colleagues while neither a single NPS nor single saliva sample was 100% sensitive for COVID-19 detection in another study (Kim et al., 2020) .

The median Ct values observed by Barra (Barra et al., 2021) . Higher viral load in the NPS samples was evident in multiple cohorts (Tapia et al., 2021; Van Vinh Chau et al., 2020) . Furthermore, alternatives such as mouth rinses and gargles were also observed to

give a better diagnosis of the infection over saliva samples (Goldfarb et al., 2021) .

A select number of studies have investigated the potential of saliva to be used as a sample for POC COVID-19 testing ( 

Another study compared the results of RT-LAMP with RT-PCR using 30 positive and 30 negative clinical saliva samples and found a 100%

PPA and a 96.7% NPA between the two different tests (Toppings et al., 2021) . 

The use of COVID-19 rapid antigen tests has especially amassed an increasing demand throughout the course of the pandemic, and as a result, several studies have investigated the use of saliva as a testing specimen for commercial SARS-CoV-2 antigen detection assays.

12/146 of the included studies in this scoping review evaluated the performance of saliva samples in commercial SARS-CoV-2 rapid antigen tests. Immunochromatographic assays, such as the Espline SARS-CoV-2 rapid antigen test (Fujirebio), were one of the more commonly tested SARS-CoV-2 POC tests in these studies using saliva as a biological specimen. 3/5 studies that tested the Espline SARS-CoV-2 assay reported low sensitivity values ranging from 11.7% to 33.0% (Ishii et al., 2021; Nagura-Ikeda et al., 2020; Yokota et al., 2021) . However, another study reported a concordance rate of 95.1% with viral culture results. (Uwamino et al., 2021) . for Spike-f, S1,NC-C, Combination antigen, etc.)

The best results declared by the authors were as: Spike-f showed 88% sensitivity and 100% specificity. NC-C showed 66% sensitivity and 100% specificity. The spike-f, S1, NC-C triple combination, showed 72% sensitivity and 100% specificity.

Caulley et al. The sensitivity for IgG antibodies to spike and RBD were 89% and 85%, respectively, while the sensitivity of the assays for IgA antibodies to spike and RBD were 51% and 30%, respectively, and the sensitivity of the assays for IgM antibodies to spike and RBD were 57% and 33%, respectively.

Keuning et al.

Saliva was collected using a buccal swab Near-infrared-fluorescence amplification by nanostructured plasmonic gold substrates IgM, IgG, and IgG avidity against the S1 subunit of the spike protein

The pGOLD SARS-CoV-2 IgG/IgM showed near 100% sensitivity 99.78% specificity MacMullan et al. (Amendola et al., 2021; Basso et al., 2021; Ishii et al., 2021; Yokota et al., 2021 Yokota et al., , 2021 . With respect to specificity values, the studies that measured specificity using COVID-19-negative saliva samples reported values of 94.1%, 96.9%, and 98.6% (Amendola et al., 2021; Basso et al., 2021; Ishii et al., 2021) . Furthermore, one study compared the diagnostic performance of the Lumipulse SARS-CoV-2 antigen kit to RT-qPCR with a saliva sample size of 2056 and found a 98.2% concordance rate between the two diagnostic tests (Yokota et al., 2021) . The Elecsys SARS-CoV-2 Antigen assay (Roche), a electrochemiluminescence immunoassay, was also evaluated using saliva specimens in a study that found 100% PPA with RT-PCR of NPS samples having Ct values of less than 26 only, while the overall PPA was reported to be 40.2% .

Some studies included in this scoping review have explored techniques using saliva for anti-SARS-CoV-2 antibody screening ( Table 3) .

Our findings confirmed that, combined with direct SARS-CoV-2 detection methods used for identifying currently infected COVID-19

patients, anti-SARS-CoV-2 antibody detection using saliva could provide a rapid and non-invasive alternative method for differentiating between non-infected, previously infected, and presently infected patients. To readily identify antibody responses in serum and saliva of SARS-CoV-2 patients, standard ELISA (enzyme-linked immunosorbent assay) methods have been modified to be more sensitive to the high-quality S protein and used as a tool for short-term and long-term humoral immunity (Faustini et al., 2021) . MacMullan and colleagues concluded that following their optimized protocol in saliva samples, antibodies against SARS-CoV-2 were detectable with a sensitivity of at least 84.2% and a specificity of 100% in sympto- argue that a combination of RNA detection with antibody testing may be required for optimal detection (Ter-Ovanesyan et al., 2021) . In one study, Ter-Ovanesyan and colleagues entertained the idea of using the same saliva sample to develop an efficient saliva RNA extraction and an antibody test. In doing so, they used singlemolecule array (SIMOA) technology and concluded that the RNA and antibody-paired detection identifies the virus at a higher sensitivity than each method alone (Ter-Ovanesyan et al., 2021) .

In this regard, Faustini and colleagues attest that without such a sensitive method, detection of responses in asymptomatic patients may be suboptimal and less reliable than the PCR tests (Faustini et al., 2021) . They suggest that a native-like, trimeric S antigen is preferred to the N antigen for detection of antibodies and that, if the detection of one Ig is run in parallel with others, their combined detection enhances antibody recognition (Faustini et al., 2021) . The persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in patients was confirmed by Isho and colleagues as they indicated that those antibodies, especially IgG, may be maintained in patients for months post-symptom onset (Isho et al., 2020) . Based on their findings, they suggested that IgG responses in saliva are a good representative measure for systemic immunity to SARS-CoV-2 due to the correlation with the serum IgG responses. As a complementary population-based approach, surveys on mucosal immunity revealed that salivary IgG against SARS-CoV-2 persists even at 9 months after mild COVID-19 infections (Alkharaan et al., 2021) . Moreover, salivary IgA appeared to be short-lived, while specific salivary IgG was stable after mild COVID-19 and therefore presents an opportunity for noninvasive, self-collective saliva testing (Alkharaan et al., 2021). Liu and colleagues quantified the antibody avidities and its accurate detection of SARS-CoV-2 antibodies in serum and saliva using a high-performance semi-quantitative assay . They specifically detected IgG, IgM, and IgA avidity against the S1 sub- 

RT-qPCR is widely known today as a laboratory technique during which an RNA sequence is reverse transcribed to make complimentary DNA, which is further amplified by polymerase chain reaction.

For SARS-CoV-2, as described earlier, RT-PCR is considered the standard for diagnosis as several specific mRNAs can be targeted for its detection, such as the mRNAs of ORF1b and the N and E structural proteins (Figure 2) . Thus, various recommendations have been made for diagnostic testing of COVID-19 by different organizations (Corman et al., 2020; Okamaoto et al., 2020) . From the selected articles, there is a clear ambiguity in the method of sample collection and the target for SARS-CoV-2 detection using saliva. Some researchers used drooling saliva to collect the samples as it eliminated the mucous secretions from the oropharynx and lower respiratory tract (Azzi et al., 2020a (Azzi et al., , 2020b . Others collected patient saliva by clearing of throat as soon as possible after waking up, before breakfast and brushing to include both bronchopulmonary secretions and nasopharyngeal secretions Wong et al., 2020) . Furthermore, the time point of sample collection, the severity, and stage of disease have also been variable across the studies . There is uncertainty in the evidence for assessing the potential of saliva as a diagnostic tool, attributing to the variabilities in methodologies. In conclusion, it can be said that saliva is a reliable F I G U R E 2 Image of SARS-CoV-2 showing its structural and genetic composition. Real-time PCR COVID-19 tests utilize the gene expression signal by detecting the mRNA for various structural proteins including spike (S), envelope (E), or nucleocapsid (N), and non-structural proteins such as ORF1ab. The magnified view shows the RNA expression sequence of the SARS-CoV-2 coronavirus with localization of various mRNA targets. Image derived from Kubina and Dziedzic (2020) tool for COVID-19 detection but both NPS and saliva specimens should be taken for screening and diagnosis, while gargle and mouth rinse can be another alternative.

POC testing has been defined in the literature as diagnostic tests that are conducted "outside the laboratory at or near the site of patient care, including the patient's bedside, the doctor's office, and the patient's home" (Khurshid, 2018) . As the current method of testing that is most well-documented and accepted by medical staff and the scientific community, RT-PCR testing continues to be the most well-established methodology for COVID-19 diagnostics and offers the highest reliability among POC testing options. However, the high equipment cost, training required for interpretation of results, and longer turnaround time continue to limit its use mostly to mass-testing facilities with access to trained laboratory personnel and equipment (Carter et al., 2020) . Current RT-PCR-based POC COVID-19 tests require specialized equipment for analyzing results that may only be attainable in healthcare and laboratory settings.

In comparison, RT-LAMP-based tests offer results that may be easily interpreted by non-laboratory trained staff and faster turnaround time relative to RT-PCR-based tests but lack the research background and large-scale clinical validation needed to scale-up its usage (Dao Thi et al., 2020) . The low cost and high reliability of currently available RT-LAMP POC test kits may potentially allow employment of this testing method in hospital, clinical, and pre-travel settings. However, challenges behind building, distributing, and administering RT-LAMP-based tests may not favor their use in common workplace or social settings compared to rapid antigen tests.

Rapid antigen tests are another method through which one targets a specific macromolecule of the virus, such as the highly conserved spike protein (Jacobs et al., 2020) . The sampling method is similar to PCR-based methods in that detection depends on the viral load but is advantageous in that it requires no specific equipment nor highly trained personnel. In this method, just like any other chromatographic method, a mobile phase (buffer mixed with the biological specimen) migrates through a stationary phase (e.g., nitrocellulose) tagged with antibodies against the viral antigens. If the viral antigens are present, they attach the antibodies and their accumulation can be detected by a visible chemical reaction which appears on the nitrocellulose membrane. The current CDC (Centers for Disease Control and Prevention) guidelines state that rapid antigen tests are commonly employed in congregate settings such as dormitories, nursing homes, correctional facilities, and homeless shelters to screen for COVID-19 infections. Due to the low turnaround time ranging from 15 to 30 min and low cost per test, rapid antigen tests offer the main benefit of rapidly identifying infected individuals in the community and workplace setting to prevent transmission and assist infection control measures. However, the overall lower sensitivity of rapid antigen tests suggests that asymptomatic individuals who test negative may require confirmatory laboratory testing using nucleic acid amplification tests (Corman et al., 2021) .

From this scoping review, it is evident that the current literature supports the use of saliva as an alternative specimen when compared to NPS for SARS-CoV-2 detection. Utilizing an optimized, saliva-based, rapid or POC kit may help overcome many current pandemic challenges while dealing with the newly emerging SARS-CoV-2 variants.

None to declare. 

The peer review history for this article is available at https://publons.com/publon/10.1111/odi.14216.

https://orcid.org/0000-0001-8790-8502

Simon D. Tran https://orcid.org/0000-0001-5594-359X

Aita, A., Basso, D., Cattelan, A. M., Fioretto, P., Navaglia, F., Barbaro, F., Stoppa, A., Coccorullo, E., Farella, A., Socal, A., Vettor, R., & Plebani, M. (2020). SARS-CoV-2 identification and IgA antibodies in saliva: One sample two tests approach for diagnosis. Clinica Chimica Acta, 510, 717-722. https://doi.org/10.1016/j.cca.2020.09.018 Al Suwaidi, H., Senok, A., Varghese, R., Deesi, Z., Khansaheb, H., Pokasirakath, S., Chacko, B., Abufara, I., Loney, T., & Alsheikh-Ali, A. 

Saliva is a valid alternative to nasopharyngeal swab in chemiluminescence-based assay for detection of SARS-CoV-2 antigen

Sensitivity of the molecular test in saliva for detection of COVID-19 in pediatric patients with concurrent conditions

The diagnostic accuracy of saliva testing for SARS-CoV-2: A systematic review and meta-analysis

Reduced relative sensitivity of the Elecsys SARS-CoV-2 antigen assay in saliva compared to nasopharyngeal swabs. Microorganisms

May viral load detected in saliva in the early stages of infection be a prognostic indicator in COVID-19 patients

A saliva-based RNA extraction-free workflow integrated with Cas13a for SARS-CoV-2 detection

Rapid salivary test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study

Saliva is a reliable tool to detect SARS-CoV-2

Performance of severe acute respiratory syndrome coronavirus 2 real-time RT-PCR tests on oral rinses and saliva samples

Pooled saliva specimens for SARS-CoV-2 testing

Overcoming supply shortage for SARS-CoV-2 detection by RT-qPCR

Salivary SARS-CoV-2 antigen rapid detection: A prospective cohort study

Saliva for diagnosis of SARS-CoV-2: First report from India

Conventional Naso-oropharyngeal sampling versus self-collected saliva samples in COVID-19 testing

Environmental and aerosolized severe acute respiratory syndrome coronavirus 2 among hospitalized coronavirus disease 2019 patients

Evaluation of self-collected midturbinate nasal swabs and saliva for detection of SARS-CoV-2 RNA

Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19

Saliva is comparable to nasopharyngeal swabs for molecular detection of SARS-CoV-2

Performance of selfcollected saliva testing compared with nasopharyngeal swab testing for the detection of SARS-CoV-2

Assay techniques and test development for COVID-19 diagnosis

Assessment of multiplex digital droplet RT-PCR as a diagnostic tool for SARS-CoV-2 detection in nasopharyngeal swabs and saliva samples

Comparison of nasopharyngeal and saliva swabs for the detection of RNA SARS-CoV-2 during mass screening (SALICOV study)

sid=OVID:medli ne&id=pmid:33582 823&id=doi:&issn=1121-7138&isbn=&volum e=44&issue =1&spage =59&pages =59-61&date=2021&title =New+Micro biolo gica&atitl e=Compa rison +of+nasop haryn geal+and+saliv a+swabs +for+the+detec tion+of+RNA+SARS-CoV-2+durin g+mass+scree ning+%28SAL ICOV+study %29.&aulas t=-Caste lain

Salivary testing of COVID-19: evaluation of serological testing following positive salivary results

Use of saliva for diagnosis and monitoring the SARS-CoV-2: A general perspective

The natural history and transmission potential of asymptomatic SARS-CoV-2 infection

Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2

A rapid, simple, inexpensive, and mobile colorimetric assay COVID-19-LAMP for mass on-site screening of COVID-19

Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study

Detection of 2019 novel coronavirus (2019-nCoV) by realtime RT-PCR

Mouth washing impaired SARS-CoV-2 detection in saliva

High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection

A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples

SARS-CoV-2 saliva testing is a useful tool for Covid-19

Self-collected unstimulated saliva, oral swab

Minimally instrumented SHERLOCK (miSH-ERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants

Concordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing

Does sampling saliva increase detection of SARS-CoV-2 by RT-PCR? Comparing saliva with oro-nasopharyngeal swabs

Self-collected saliva for SARS-CoV-2 detection: A prospective study in the emergency room

Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. MedRxiv: The Preprint Server for Health Sciences

Comparison of SARS-CoV-2 PCR-based detection using saliva or nasopharyngeal swab specimens in asymptomatic populations

Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva

Performance of saliva as a specimen to detect SARS-CoV-2

Performance of saliva specimens for the molecular detection of SARS-CoV-2 in the community setting: does sample collection method matter

Performance of RT-PCR on Saliva specimens compared with nasopharyngeal swabs for the detection of SARS-CoV-2 in children: A prospective comparative clinical trial

Efficacy of a novel SARS-CoV-2 detection kit without RNA extraction and purification

A comparison of less invasive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic specimens in nursing home residents-Arkansas

Reverse transcription loop-mediated isothermal amplification assay for ultrasensitive detection of SARS-CoV-2 in saliva and viral transport medium clinical samples

Buccal swabs as non-invasive specimens for detection of severe acute respiratory syndrome coronavirus-2

Selfcollected saline gargle samples as an alternative to health care worker-collected nasopharyngeal swabs for COVID-19 diagnosis in outpatients

COVID-19 diagnosis by RT-qPCR in alternative specimens

Evaluation of specimen types and saliva stabilization solutions for SARS-CoV-2 testing

Comparison of saliva and oro-nasopharyngeal swab sample in the molecular diagnosis of COVID-19

Suitability and sufficiency of telehealth clinician-observed, participant-collected samples for SARS-CoV-2 testing: The iCollect cohort pilot study

Gargle lavage & saliva: Feasible & cheaper alternatives to nasal & throat swabs for diagnosis of COVID-19

COVID-19 pandemic and role of human saliva as a testing biofluid in point-of-care technology

Saliva-friend and foe in the COVID-19 outbreak

SARS-CoV-2 presence in the saliva, tears, and cerumen of COVID-19 patients

Self-collected anterior nasal and saliva specimens versus healthcare workercollected nasopharyngeal swabs for the molecular detection of SARS-CoV-2

Saliva is a reliable and accessible source for the detection of SARS-CoV-2

Comparison of throat washings, nasopharyngeal swabs and oropharyngeal swabs for detection of SARS-CoV-2

High efficacy of saliva in detecting SARS-CoV-2 by RT-PCR in adults and children

Early-morning vs spot posterior oropharyngeal saliva for diagnosis of sars-cov-2 infection: implication of timing of specimen collection for community-wide screening

Immunochromatography and chemiluminescent enzyme immunoassay for COVID-19 diagnosis

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva

Implementing COVID-19 (SARS-CoV-2) rapid diagnostic tests in Sub-Saharan Africa: A review

Sensitivity of midturbinate versus nasopharyngeal swabs for the detection of severe acute respiratory

Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2

Saliva as a diagnostic tool for oral and systemic diseases

Saliva testing is accurate for earlystage and presymptomatic COVID-19

Comparison of viral load between saliva and nasopharyngeal swabs for SARS-CoV2: The role of days of symptoms onset on diagnosis

Detection of SARS-CoV-2 from saliva as compared to nasopharyngeal swabs in outpatients

Saliva SARS-CoV-2 antibody prevalence in children

Salivary point-of-care technology

Human saliva: Non-invasive fluid for detecting novel coronavirus (2019-nCoV)

Viral load kinetics of SARS-CoV-2 infection in saliva in Korean patients: A prospective multi-center comparative study

A novel saliva RT-LAMP workflow for rapid identification of COVID-19 cases and restraining viral spread

Self-collected oral fluid and nasal swab specimens demonstrate comparable sensitivity to cliniciancollected nasopharyngeal swab specimens for the detection of SARS-CoV-2

Validation of self-collected buccal swab and saliva as a diagnostic tool for COVID-19

Molecular and serological tests for COVID-19. A comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics

Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure

Comparison of saliva with oral and nasopharyngeal swabs for SARS-CoV-2 detection on various commercial and laboratorydeveloped assays

Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients

Reliable detection of SARS-CoV-2 with patient-collected swabs and saline gargles: A three-headed comparison on multiple molecular platforms

Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2

Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

Detection of SARS-CoV-2 antibodies in oral fluid obtained using a rapid collection device

ELISA detection of SARS-CoV-2 antibodies in saliva

Evaluation of RNA extraction-free method for detection of SARS-CoV-2 in salivary samples for mass screening for COVID-19

SARS-CoV-2 cysteine-like protease antibodies can be detected in serum and saliva of COVID-19-seropositive individuals

Detection of severe acute respiratory syndrome Coronavirus 2 on self-collected saliva or anterior nasal specimens compared with healthcare personnelcollected nasopharyngeal specimens

Are posterior oropharyngeal saliva specimens an acceptable alternative to nasopharyngeal sampling for the monitoring of SARS-CoV-2 in primary-care settings?

Practical challenges to the clinical implementation of saliva for SARS-CoV-2 detection

Saliva as an alternate specimen source for detection of SARS-CoV-2 in symptomatic patients using cepheid xpert xpress SARS-CoV-2

Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities

Evaluating diagnostic accuracy of saliva sampling methods for severe acute respiratory syndrome coronavirus 2 reveals differential sensitivity and association with viral load

Testing individual and pooled saliva samples for sars-cov-2 nucleic acid: A prospective study

Diagnostic accuracy of fresh drooled saliva for SARS-CoV-2 in travelers

Saliva sampling and its direct lysis, an excellent option to increase the number of SARS CoV2 diagnostic tests in settings with supply shortages

Diagnostic accuracy and acceptability of molecular diagnosis of COVID-19 on saliva samples relative to nasopharyngeal swabs in tropical hospital and extra-hospital contexts: The COVISAL study

Prospective comparison of saliva and nasopharyngeal swab sampling for mass screening for COVID-19

Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19

Effective screening strategies for detection of asymptomatic COVID-19 travelers at airport quarantine stations: Exploratory findings in Japan

Assessment of real-time RT-PCR kits for SARS-CoV-2 detection

Adding saliva testing to oropharyngeal and deep nasal swab testing increases PCR detection of SARS-CoV-2 in primary care and children

Detection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples

Saliva testing is a robust noninvasive method for SARS-CoV-2 RNA detection

Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: A cross-sectional study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases

Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: A cross-sectional study

Performances, feasibility and acceptability of nasopharyngeal swab, saliva and oral-self sampling swab for the detection of severe acute respiratory syndrome coronavirus 2

Multiplatform assessment of saliva for SARS-CoV-2 molecular detection in symptomatic healthcare personnel and patients presenting to the emergency department

Detection of SARS-CoV-2 infection in gargle, spit, and sputum specimens

A direct comparison of enhanced saliva to nasopharyngeal swab for the detection of SARS-CoV-2 in symptomatic patients

Diagnostic accuracy of loop-mediated isothermal amplification coupled to nanopore sequencing (LamPORE) for the detection of SARS-CoV-2 infection at scale in symptomatic and asymptomatic populations

COVID-19 screening test by using random oropharyngeal saliva

Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Comparing nasopharyngeal swab and early morning saliva for the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Evaluation of SARS-CoV-2 antigen-based rapid diagnostic kits in Pakistan: formulation of COVID-19 national testing strategy

Clinical validation of a sensitive test for saliva collected in healthcare and community settings with pooling utility for severe acute respiratory syndrome coronavirus 2 mass surveillance

Detection of SARS-CoV-2 RNA using RT-qPCR in nasopharyngeal swab, saliva, lingual, and buccal mucosal swab

Comparison of saliva with healthcare workers-and patient-collected swabs in the diagnosis of COVID-19 in a large cohort

Saliva as an alternative specimen for molecular COVID-19 testing in community settings and population-based screening

Effects of patient characteristics on diagnostic performance of self-collected samples for SARS-CoV-2 testing

Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19

Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test

The effect of sample site, illness duration, and the presence of pneumonia on the detection of SARS-CoV-2 by real-time reverse transcription PCR

Performance of saliva samples for COVID-19 diagnosis by using the allplex ™ 2019-nCoV assay kit

Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection

Ultrasensitive measurement of both SARS-CoV-2 RNA and antibodies from saliva

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. The Lancet Infectious Diseases

A rapid near-patient detection system for SARS-CoV-2 using saliva

PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation

Self-collection of saliva specimens as a suitable alternative to nasopharyngeal swabs for the diagnosis of SARS-CoV-2 by RT-qPCR

Saliva samples for detection of SARS-CoV-2 in mildly symptomatic and asymptomatic patients

Diagnosing COVID-19: The disease and tools for detection

Accuracy of rapid antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with RT-PCR and viral culture for SARS-CoV-2 detection

The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection

Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection

Validation of the GeneXpert Xpress SARS-CoV-2 PCR assay using saliva as biological specimen

Saliva is inferior to nose and throat swabs for SARS-CoV-2 detection in children

Saliva as a noninvasive specimen for detection of SARS-CoV-2

Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay

Posterior oropharyngeal saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2

A rapid, accurate, scalable, and portable testing system for COVID-19 diagnosis

Development of a point-of-care test to detect SARS-CoV-2 from saliva which combines a simple RNA extraction method with colorimetric reverse transcription loop-mediated isothermal amplification detection

Saliva TwoStep for rapid detection of asymptomatic SARS-CoV-2 carriers. eLife

Saliva is a promising alternative specimen for the detection of SARS-CoV-2 in children and adults

Equivalent SARS-CoV-2 viral loads by PCR between nasopharyngeal swab and saliva in symptomatic patients

Performance of qualitative and quantitative antigen tests for SARS-CoV-2 using saliva

Mass screening of asymptomatic persons for severe acute respiratory syndrome coronavirus 2 using saliva

A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study

Logistic advantage of two-step screening strategy for SARS-CoV-2 at airport quarantine

Assessment of the diagnostic ability of four detection methods using three sample types of COVID-19 patients

Saliva as a diagnostic specimen for SARS-CoV-2 detection: A scoping review